X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs MYLAN (US) - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN LTD   MYLAN
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
MYLAN
Dec-14
LUPIN LTD/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,7503,830-   
Low Rs1,3842,699-   
Sales per share (Unadj.) Rs387.41,311.3-  
Earnings per share (Unadj.) Rs56.6158.0-  
Cash flow per share (Unadj.) Rs76.8254.3-  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs298.9651.9-  
Shares outstanding (eoy) m451.58378.37-   
Bonus/Rights/Conversions ESOPSOI-  
Price / Sales ratio x4.02.5 162.4%   
Avg P/E ratio x27.720.7 133.9%  
P/CF ratio (eoy) x20.412.8 158.8%  
Price / Book Value ratio x5.25.0 104.7%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m707,5131,235,346 57.3%   
No. of employees `00016.825.0 67.2%   
Total wages/salary Rs m28,4950-   
Avg. sales/employee Rs Th10,418.319,846.6 52.5%   
Avg. wages/employee Rs Th1,697.00-   
Avg. net profit/employee Rs Th1,523.02,390.8 63.7%   
INCOME DATA
Net Sales Rs m174,943496,164 35.3%  
Other income Rs m1,065-2,892 -36.8%   
Total revenues Rs m176,008493,272 35.7%   
Gross profit Rs m44,931123,398 36.4%  
Depreciation Rs m9,12236,441 25.0%   
Interest Rs m1,52521,402 7.1%   
Profit before tax Rs m35,34962,663 56.4%   
Minority Interest Rs m-72-257 27.9%   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7852,635 371.3%   
Profit after tax Rs m25,57559,771 42.8%  
Gross profit margin %25.724.9 103.3%  
Effective tax rate %27.74.2 658.3%   
Net profit margin %14.612.0 121.4%  
BALANCE SHEET DATA
Current assets Rs m119,542436,194 27.4%   
Current liabilities Rs m61,206341,017 17.9%   
Net working cap to sales %33.319.2 173.8%  
Current ratio x2.01.3 152.7%  
Inventory Days Days7678 97.4%  
Debtors Days Days90107 83.8%  
Net fixed assets Rs m131,660114,786 114.7%   
Share capital Rs m90317,546 5.1%   
"Free" reserves Rs m134,0730-   
Net worth Rs m134,976246,643 54.7%   
Long term debt Rs m56,478368,460 15.3%   
Total assets Rs m266,073993,454 26.8%  
Interest coverage x24.23.9 615.5%   
Debt to equity ratio x0.41.5 28.0%  
Sales to assets ratio x0.70.5 131.6%   
Return on assets %10.28.2 124.7%  
Return on equity %18.924.2 78.2%  
Return on capital %19.313.6 141.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m60,3780-   
CASH FLOW
From Operations Rs m41,14865,221 63.1%  
From Investments Rs m-25,287-51,435 49.2%  
From Financial Activity Rs m4,332-17,186 -25.2%  
Net Cashflow Rs m20,193-3,400 -593.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare LUPIN LTD With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare LUPIN LTD With: ORCHID PHARMA LTD  PFIZER  IPCA LABS  SHASUN PHARMA  WOCKHARDT LTD.  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - AJANTA PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS